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A new chemogenetic treatment for inhibition of pain signaling in the peripheral nervous 
system will be tested using a spinal cord injury model. More than half of spinal cord injury 
patients experience chronic neuropathic pain that is refractory to treatment. This pain is thought 
to arise after spinal cord injury due to the uncontrolled signaling of nociceptors, a class of 
peripheral sensory neurons that send pain signals to the central nervous system. Previous 
research has shown that hyperactivity of nociceptors in the acute phase of injury can prevent 
long term motor recovery and lead to chronic pain. The goal of this study is to silence these 
miscommunicating pain neurons using viral vector (AAV6)-mediated gene delivery to 
nociceptors. We used this approach to deliver a gene encoding a designer receptor exclusively 
activated by designer drugs (Gi-DREADD). This receptor silences neuron activity when bound 
to an inert ligand that is injected into the rat. This virus has been reported to be highly selective 
for nociceptors in mice by another group. However, the virus has not previously been tested in a 
spinal cord injury model.  
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We have performed three studies to determine: (1) the selectivity of AAV6-mediated 
gene delivery to transduce peripheral nociceptors with Gi-DREADD, (2) the efficiency of gene 
delivery using different injection techniques, and (3) the subpopulations of nociceptors that are 
transduced using this approach. We have identified optimized viral vector delivery strategies that 
yield transduction in more than 20% of nociceptors. Additionally, we have observed that AAV6 
is highly selective for nociceptors in rats, exhibiting >99% specificity for small-diameter pain 
neurons including multiple molecularly distinct subtypes of nociceptors. Finally, in a pilot 
behavioral study we found a strong and significant correlation between the proportions of 
DREADD-expressing nociceptors and inhibition of thermal pain responses. 
 
Future work will use our optimized gene delivery strategy to test whether nociceptor 
silencing with DREADDs is sufficient to prevent long-term neurological deficits after spinal 
cord injury. We predict that silencing nociceptors early after spinal cord injury in rats will reduce 
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DREADDs Designer receptors exclusively activated by designer drugs 
ISCIP  International Spinal Cord Injury Pain  
CNO  Clozapine N-oxide 
DRG  Dorsal root ganglion  
CTB  Cholera toxin subunit B 






Spinal cord injuries often occur from motor vehicle crashes, falls, firearms, and diving in 
shallow water. The resulting symptoms vary widely depending on the severity and location of 
injury. Paresis, a partial loss of voluntary movement, and paralysis, a complete loss of voluntary 
movement, are common symptoms associated with spinal cord injuries.1 Loss of motor function 
is just one of the many symptoms of spinal cord injury. Chronic pain often occurs after spinal 
cord injury, sometimes having a bigger impact on the patient’s quality of life than the 
immobilization itself.2  
 
On March 6 and 7, 2009, a group of international researchers and medical professionals 
met to define and classify the different types of spinal cord injury pain. Previously, experts had 
agreed that pain occurs after spinal cord injury, however; there was no consensus on how to 
define it. By 2002, there were 29 papers proposing different classification methods.3 A collection 
of 42 studies before 2009 showed that 26-96% of spinal cord injury patients had pain.2 
Comparisons between studies were inconsistent. The absurdly wide range of results showed the 
need for a standard classification. At the 2009 conference, they created a three-tiered system, the 
International Spinal Cord Injury Pain (ISCIP) Classification. Tier I has 3 categories: nociceptive, 




The goal of this research project focuses on preventing the development of neuropathic 
pain in a rodent spinal cord injury model. This is defined as ‘‘pain caused by a lesion or disease 
of the somatosensory nervous system.’’3 The Tier II ISCIP classification separates it into “at 
level” and “below level” pain, referring to the dermatome in which pain is consciously felt by the 
patient.2 Neuropathic pain in spinal cord injury patients is either constant and/or stimulus-
evoked. The pain can feel like a burn, a squeeze, tingle, or needle prick. Allodynia, when non-
painful stimuli cause pain, and hyperalgesia, increased sensitivity to pain, are common 
symptoms as well.4  
 
Sensory receptors (nerve endings) that respond to sensory stimuli are the processes of 
neurons within the dorsal root ganglia (DRG). These are specialized neurons of the peripheral 
nervous system that transmit sensory information from the peripheral body into the spinal cord, 
where it is then transmitted to brain regions. The class of DRG neurons that specifically respond 
to noxious, painful stimuli are referred to as nociceptors. The normal functioning of nociceptors 
is important in order to avoid painful stimuli in daily life. However, there is much evidence to 
suggest that these neurons undergo pathological changes following spinal cord injury that leads 
to detrimental outcomes. 
 
For example, it has been shown that spinal cord injury can lead to upregulation of 
Nav1.8, a voltage gated Na+ channel, in nociceptors.6 By knocking down the Nav1.8 protein, the 
hypersensitivity of withdrawal reflex was reduced, and the long term pain outcomes were 
reduced. The study showed that there are changes in protein expression occurring in the 
nociceptors that make them more prone to firing. It also showed that hyperactivity of the 
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nociceptors can lead to the development of neuropathic pain after spinal cord injury. There are 
likely many molecular processes responsible, but these are incompletely understood. 
 
Another study showed that hyperactive nociceptors can lead to inhibition of motor 
recovery as well. Applying a noxious stimulus early after spinal cord injury resulted in an 
increase of hemorrhage and apoptotic cells near the injury site.7 The mice also performed worse 
in behavior testing. Clearly, the hyperactivity of nociceptors has a negative effect on recovery.  
 
Treatments that prevent this early activation of nociceptors may prevent long term pain 
from developing and increase motor recovery. However, many of the current clinically available 
pain treatments are inadequate. One of the reasons is that there are many different mechanisms 
behind neuropathic pain, and not every patient has the same problem. There is still more to 
learn.5 Current treatments include antiepileptics, antidepressants, opioids, interventional therapy, 
and invasive surgical procedures.  
 
The antiepileptic drugs gabapentin and pregabalin are commonly given to spinal cord 
injury patients.8 Some studies have showed these drugs to be effective;9 however, others 
disagree. One study says that “Inadequate response to drug treatments constitutes a substantial 
unmet need in patients with neuropathic pain. Modest efficacy, large placebo responses, 
heterogeneous diagnostic criteria, and poor phenotypic profiling probably account for moderate 
trial outcomes.”10 For some patients, antiepileptic drugs may help; however, they are not 
completely effective.  
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Tricyclic antidepressants are another common treatment option. However, studies have 
not shown promising results. One showed that they have no effect11 and another showed that 
they only work to reduce neuropathic pain in depressed patients.12 Despite their inadequacies, 
they are given frequently because they are relatively safe.8  
 
Opioids provide pain relief but are not a good option for chronic treatment. Tolerance to 
the drugs develops, as well as physical and psychological dependence. Also, death from 
overdoses can occur. Opioid-induced hyperalgesia can even increase pain. On top of that, long 
term use has been shown to cause endocrine problems.13 Dr. Hook at Texas A&M University has 
also shown that morphine given in the acute phase of spinal cord injury further inhibits recovery 
of motor function.14 
 
Intrathecal injections of baclofen are known to help musculoskeletal pain in spinal cord 
injury but there is no evidence to say they are effective for neuropathic pain.15 Nerve blocks 
work well for at-level pain management, but they wear off within a year. There is always a 
chance of iatrogenic injury.16 The side effects cause metabolic, endocrine, immunologic, and 
psychological issues.8  
 
Spinal cord stimulation is another potential treatment for neuropathic pain. While there 
have been positive results in animal models, it has not been tested well enough in spinal cord 
injury models.17 Further research may show it to be a possible treatment. Unfortunately, none of 
the current treatments are appropriate for inhibiting the nociceptors early after spinal cord injury.  
 
9 
A new treatment option may be possible using DREADD technology.18 Designer 
receptors exclusively activated by designer drugs (DREADDs; also referred to as 
‘chemogenetics’) are a recently developed technology for the selective silencing or activation of 
neurons.  The DREADD used in this study is a modified, Gi-coupled M4 muscarinic receptor 
[hM4d(Gi)] that allows neurons to be controlled by opening K+ channels that hyperpolarize the 
neuron, but only upon binding of an otherwise inert compound, clozapine-N-oxide (CNO).19 
Expression of Gi-DREADD therefore allows neurons to be silenced for a period of several hours 
following the systemic delivery of CNO to the animal.  
 
One study recently showed that the hM4d(Gi) receptor can be used to selectively silence 
nociceptors using a specific delivery method.18 The authors took advantage of the high tropism 
of adeno-associated virus, serotype 6 (AAV6) to deliver DREADDs to nociceptors with very 
high selectivity. Based on these results, we sought to apply this strategy in a spinal cord injury 
model in order to prevent hyperactivity of nociceptors.  
 
In this study, we used AAV6 to selectively deliver hM4d(Gi)-DREADD to nociceptors of 
uninjured rats in order to validate this delivery strategy with the ultimate goal of applying it to 
spinal cord injured rats. We tested the specificity of this approach to deliver DREADDs to 
nociceptors of rats, and optimized our delivery protocol to increase the numbers of infected 
neurons. A pilot behavior study with rats demonstrated the functional efficacy of nociceptors. 
Future work will look for functional sensory and motor improvements following acute 
nociceptor silencing after spinal cord injury. Silencing the nociceptors using DREADDs has 





 Adult, female Fischer 344 rats weighing approximately 150g were used for all 
experiments. A total of 16 rats were used for this project. All animal experiments were approved 
by the Texas A&M University Institutional Animal Care & Use Committee (Animal Use 
Protocol #2018-0014). National Institutes of Health guidelines for laboratory animal care and 
safety were strictly followed.  
 
First, we injected rats’ sciatic nerves with 1.2 x 1013 viral genome copies (gc)/mL 
AAV6-hM4d(Gi)-DREADD-mCitrine (University of North Carolina viral vector core). The 
sensory axons in the sciatic nerve are derived from soma in the L4-L6 dorsal root ganglia (Figure 
1). The virus was suspended in 0.1% w/v cholera toxin subunit B (CTB). This molecule is taken 
up at the injection site and travels to the neuronal cell bodies. It is used as a control to show if the 
injection was accurate. A blue dye was also added to help see the injection solution during 
surgery (Figure 2). A Hamilton syringe was used to inject 2 l into the sciatic nerve by hand. 3 
weeks after injection, the rats were sacrificed and the L4-L6 DRG were dissected and stained 
























Figure 1. Illustration showing the injection point in 
the sciatic nerve connecting to the L4-L6 DRG. 
 
Figure 2. A sciatic nerve being injected 
with AAV suspended in a blue dye for 
enhanced visualization. 
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In a second round of preliminary testing, the method of virus delivery was modified to try 
to optimize efficiency of gene delivery. More virus was injected, and a pressure driven 
microinjector, a picospritzer, was used instead of delivery by hand. Total delivery volume was 
increased to 4 l per nerve. In a pilot study, we tested these animals’ behavioral responses to a 
painful thermal stimulus before and after DREADD activation.  
 
For the behavior study in the second round of testing, the Hargreaves apparatus was 
used.20 The Hargreaves test assesses thermal pain sensation in the rats. An emitter uses infrared 
light to heat the paw of the rat. The time it takes for the rat to withdraw its paw is recorded. The 
rat will usually look at or lick its paw in response to the stimulus. A baseline pain threshold was 
taken before and after delivering the DREADD ligand, clozapine N-oxide (CNO),  to see if the 
DREADD reduced nociceptor activity. Animals were sacrificed following behavior testing; the 
tissue was then harvested and analyzed immunohistochemically.  
 
To further boost the efficiency of our gene delivery strategy, the third round of 
preliminary testing used a high salt method (0.6 M NaCl) of AAV delivery recommended by Dr. 
Jeffrey Twiss (University of South Carolina) who recently used AAV to successfully infect DRG 
neurons 21. The rats were also injected at multiple points along the sciatic nerve to increase the 
amount of virus taken up by the neurons.  
 
Resources used for this project came from the Dulin Lab. Jennifer Dulin monitored the 






 The first round of injections was delivered by hand to 6 rats, which gave 12 sets of DRGs 
to analyze (left and right L4-L6 DRGs). Only 4 of the 12 sets showed any sign of DREADD 
expression as determined by expression of the mCitrine fluorescent reporter protein. Many types 
of neurons took up the CTB (Figure 3), which shows that the injection worked for those rats. In 
those 8 sets not showing infection, there was no mCitrine or CTB. Since there was no sign of the 
control, CTB, it meant that our injection technique needed to be improved. Of those DRGs that 
contained mCitrine-expressing neurons, the total number of neurons was lower than expected. 
Only 4.05% of the nociceptors in the DRG were infected. Iyer et al. had previously reported a 
25.1% infection rate of nociceptors22. The low rate of infection was likely due to the volume of 
virus used (2 l) and the leakage that occurred when delivering the virus with a Hamilton 
syringe. 
Figure 3. An example of a DRG with infected nociceptors (mCitrine) and neurons with CTB. 
14 
 Despite the low infection rates, 33.1% of the infected nociceptors also were CGRP+ 
neurons. Only certain subsets of nociceptive neurons are CGRP+. Iyer et al. previously reported 
that 33% of their infected nociceptors CGRP+ which was very similar.22 The AAV is clearly 
showing a similar specificity for infected nociceptor type in both rats and mice.  
 
 A second round of injections was performed to raise the number of infected nociceptors. 
The second round of injections used more virus (4 l) and a picospritzer for delivery. The results 
were much better. Out of 10 sets of DRGs, all but one contained infected nociceptors. Also, the 
infection rate jumped up to an average of 6.52% of neurons (Figure 4). The diameter of 
nociceptors infected was r quantified and we observed that small diameter neurons were 
exclusively infected (Figure 5). This was also observed qualitatively in the first round of 
injections; it was not quantified though. 
 

















Figure 5. DREADD-infected neurons are small-diameter, showing AAV6 has tropism for only 
nociceptors. a) yellow cells are infected neurons (mCitrine), and pink cells are all DRG neurons 
(NeuN). b) graph of diameter averages for 5 rats. 
 
Figure 6. Correlation of nociceptor DREADD expression with 
CNO-associated analgesia. Average of both hindlimbs; n=4. 
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 Sensory assessments were performed on the rats from the second trial (Figure 6). A 
modified Hargreaves apparatus was used to assess latency to withdraw hind paws from a noxious 
thermal stimulus. Behavioral responses were assessed in 4 animals before and after CNO 
delivery. It was expected that the DREADD would decrease pain sensation in the rats. The data 
from the graph shows the direct relationship between the infection rate and the fold change in 
withdrawal latency (post-CNO latency / pre-CNO latency). The one rat that had DREADD 
expressed in 6.75% of its nociceptors showed a 2.5-fold change in withdrawal latency after CNO 
delivery, indicating strong effects of DREADD activation on inhibition of pain signaling. 
Animals with fewer numbers of DREADD-expressing nociceptors exhibited a lower fold-change 
in thermal latency. We found that there was a significant correlation between the numbers of 
DREADD+ neurons in each animal and that individual animal’s fold-change in thermal latency. 
One thing to note is that the other paper that used this virus was getting a higher infection rate. 
Despite these rats’ low infection rate, the efficacy of the DREADD was still demonstrated. 
 
One more preliminary trial was performed using a high salt concentration (0.6 M NaCl). 
The lab has started analyzing the images from the staining process in order to determine whether 











Spinal cord injury patients commonly have neuropathic pain associated with their 
injuries. Studies have shown that hyperactive nociceptors early after injury can play a role in this 
pain. In addition to long term pain, their stimulation can cause inflammation and increase the 
number of apoptotic cells near the injury site, which can inhibit locomotor recovery. 
 
We predicted that silencing nociceptors early after spinal cord injury would reduce long-
term pain outcomes and lead to functional recovery. Before we could begin testing the 
chemogenetic treatment on spinal cord injury rats, we needed to make sure it worked. So far, we 
have accomplished testing the AAV6-hM4d-DREADDs, ensuring that they are infecting the 
correct cells at a high enough rate to work effectively.  
 
The data collected shows that the virus is highly specific for nociceptors; in fact, it was 
greater than 99% specific for nociceptors. Three different methods were tested to maximize 
infection: first, injection by hand with a Hamilton syringe, second, with a picospritzer and more 
virus, and third, with a picospritzer, more virus, and a high salt solution. The third test with high 
salt solution proved to be the most effective. The future injections will use this method. When 
the rats were tested with the Hargreaves test, the 6.75% infected nociceptor rat showed a 2.5-fold 
increase in withdrawal latency after CNO addition. This pilot behavior study suggests efficacy of 
the DREADD, despite the low infection rate. The AAV6-hM4d-DREADD clearly works well; it 
infects the correct cell type at a high enough rate to show a change in pain threshold. 
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The project is ongoing, but the current data looks promising. A larger behavioral study 
will begin soon. It will test the DREADD in spinal cord injury rats to see if there is an impact on 
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